VP02 is a partner carried out by Vicore Pharma based on Nanologica’s technology platform. The aim of the project is to develop a new drug for the treatment of Idiopathic Pulmonary Fibrosis (IPF), which is a deadly disease where the patients’ lung capacity gradually decreases due to fibrosis of the pulmonary tissue. VP02 is a reformulation of thalidomide, which is an API from the IMiD family (immunomodulatory imide drugs), having both anti-inflammatory and antifibrotic properties. Clinical studies have proven thalidomide to be effective for both the coughing and quality of life for the patients.
VP02 intends to use Nanologica’s technology to deliver the API locally in the lung, which would enable lowering the dose leading the systemic exposure being lowered by 50-85% resulting in fewer side effects.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.